Standigm

Based in South Korea, Standigm, Inc. specializes in advanced AI solutions for drug discovery, expediting the development process from initial discovery through to preclinical candidate stages. Founded in 2015 in Seoul, South Korea, Standigm, Inc. focuses on AI-driven drug discovery.

The company has executed 6 deals since inception, with its latest funding round occurring on July 6, 2021, when it raised USD 10 mn led by Pavilion Capital. The founders include Jinhan Kim, Sang Song, and So Yun, with Jinhan Kim also serving as CEO. Standigm specializes in cutting-edge AI solutions for drug discovery, delivering comprehensive services that encompass the entire process from initial discovery to preclinical candidate development. Their core offerings include AI-driven target identification, lead optimization, and active material exploration, aimed at addressing significant inefficiencies in the pharmaceutical development cycle.

By leveraging its proprietary platform, Standigm has reduced the average material optimization time from approximately 4. 5 years to just 1. 5 years, thereby enhancing the speed and efficiency of drug development. The company primarily serves pharmaceutical and biotechnology firms across various global markets, including North America, Europe, and Asia, providing tailored solutions that facilitate the creation of innovative therapies.

Standigm's client base consists of research institutions and pharmaceutical companies seeking to harness AI technologies to streamline their drug discovery processes. Standigm generates revenue through a combination of subscription models and partnerships with pharmaceutical companies and research institutions. Clients typically engage with Standigm through service agreements that delineate the scope of the projects, which may include access to their AI SaaS & API solutions, such as STELLA and SPICA, for target identification and optimization tasks. These services are designed to cater to businesses looking for advanced analytical capabilities in drug development.

While specific pricing plans for these services are not disclosed, transactions are structured to ensure that clients pay for the customized solutions and ongoing support they receive, fostering long-term collaborations. The company's revenue is thus primarily derived from B2B relationships, with transactions reflecting the value of its AI-driven services in accelerating drug discovery timelines for its clients. In July 2021, Standigm, Inc. raised USD 10 mn in venture funding led by Pavilion Capital, which will be utilized for the clinical research of AI-driven drug compounds.

The company plans to expand its offerings with new products aimed at enhancing drug discovery efficacy. Furthermore, Standigm intends to enter additional markets in North America and Europe by 2023, leveraging its recent funding to support these initiatives.